M. Kraenzlin

发表

Use of beta-blockers and risk of fractures.

R. Schlienger, S. Jick, C. Meier, 2004, JAMA.

Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men

Kurt Lippuner, K. Lippuner, M. Kraenzlin, 2004, Osteoporosis International.

Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women.

C. Schindler, J. Puder, C. De Geyter, 2005, The Journal of clinical endocrinology and metabolism.

Antiepileptics and bone health

M. Kraenzlin, C. Meier, 2011, Therapeutic advances in musculoskeletal disease.

Proton Pump Inhibitors and Fracture Risk

C. Meier, M. Kraenzlin, M. Bodmer, 2010, Drug safety.

Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.

K. Lippuner, M. Kraenzlin, A. Popp, 2006, Maturitas.

Elevation of plasma epinephrine concentrations inhibits proteolysis and leucine oxidation in man via beta-adrenergic mechanisms.

U. Keller, A. Thélin, M. Arnaud, 1989, The Journal of clinical investigation.

Patients on injectable diacetylmorphine maintenance have low bone mass.

G. Wiesbeck, R. Stohler, M. Kraenzlin, 2011, Drug and alcohol review.

Use of Bone Turnover Markers in the Real World: Are We There Yet?

M. Seibel, M. Kraenzlin, C. Meier, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Is there a clinical relevance of partial androgen deficiency of the aging male?

T. Gasser, M. Trummler, M. Christ-Crain, 2004, The Journal of urology.

Long term treatment of acromegaly with a long acting analogue of somatostatin.

S. Bloom, J. Burrin, M. Kraenzlin, 1985, British medical journal.

Fibroblast growth factor 21 predicts outcome in community-acquired pneumonia: secondary analysis of two randomised controlled trials

M. Christ-Crain, P. Schuetz, Fahim Ebrahimi, 2019, European Respiratory Journal.

[FLS - three letters alter secondary fracture prevention].

N. Suhm, D. Rikli, M. Kraenzlin, 2016, Der Unfallchirurg.

Bone Microarchitecture and Strength in Long‐Standing Type 1 Diabetes

P. Zysset, K. Lippuner, M. Kraenzlin, 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health

A. Egger, M. Kraenzlin, C. Meier, 2016, Current Osteoporosis Reports.

Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation

M. Baumgartner, A. Kariminejad, C. Marcelis, 2011, Orphanet journal of rare diseases.

Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

T. Adrian, S. Bloom, M. Kraenzlin, 1985, Gut.

The Zinc Transporter SLC39A13/ZIP13 Is Required for Connective Tissue Development; Its Involvement in BMP/TGF-β Signaling Pathways

J. Beckmann, O. Ohara, T. Hirano, 2008, PloS one.

Biochemical Markers of Bone Turnover – Clinical Aspects

M. Seibel, M. Kraenzlin, C. Meier, 2010 .

Fluoride pharmacokinetics in good and poor responders to fluoride therapy

D. Baylink, M. Kraenzlin, D. Baylink, 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Quality controls for two heel bone ultrasounds used in the Swiss Evaluation of the Methods of Measurement of Osteoporotic Fracture Risk Study.

R. Rizzoli, J. Cornuz, A. Tyndall, 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[Laboratory assessment of osteoporosis].

A. Griesmacher, M. Anliker, M. Kraenzlin, 2008, Therapeutische Umschau. Revue therapeutique.

Biochemical markers of bone turnover and osteoporosis management

M. Kraenzlin, 2007 .

The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment

M. Seibel, M. Azria, H. Haas, 1996, Calcified Tissue International.

Measurement of Biochemical Markers of Bone Resorption

M. Seibel, M. Kraenzlin, 2006 .

CHAPTER 33 – Measurement of Biochemical Markers of Bone Resorption

M. Seibel, M. Kraenzlin, 2006 .

Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases.

C. Giunta, B. Steinmann, M. Kraenzlin, 2008, Clinical chemistry.

Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance.

J. Puder, C. De Geyter, U. Keller, 2005, The Journal of clinical endocrinology and metabolism.

Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting

C. Cooper, J. Reginster, R. Rizzoli, 2017, Osteoporosis International.

Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer

M. Kraenzlin, C. Meier, 2006, Expert opinion on biological therapy.

Interaction of cortisol and epinephrine in the regulation of leucine kinetics in man

U. Keller, A. Thélin, M. Arnaud, 1988, Experientia.

Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women.

J. Bonjour, M. Kraenzlin, V. Benoit, 2013, The Journal of clinical endocrinology and metabolism.

BRIEF REPORT Body Composition and Adiponectin Serum Concentrations in Adult Patients with Cystic Fibrosis

J. Puder, U. Keller, M. Tamm, 2006 .

Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis.

J. Puder, U. Keller, M. Tamm, 2006, The Journal of clinical endocrinology and metabolism.

Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.

S. Bloom, M. Kraenzlin, D. Carr, 1985, Gastroenterology.

Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones

S. Bloom, M. Ghatei, M. Kraenzlin, 1985, Regulatory Peptides.

Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma.

S. Bloom, P. Heitz, K. Gyr, 1987, Gastroenterology.

Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase.

K. Lau, F. Singer, D. Baylink, 1990, The Journal of clinical endocrinology and metabolism.

Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms

R. Rizzoli, F. Herrmann, G. Gold, 2016, Journal of Endocrinological Investigation.

Spondylocheiro dysplastic form of the Ehlers-Danlos syndrome--an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13.

N. Elçioglu, D. Eyre, B. Albrecht, 2008, American journal of human genetics.

Biochemical Markers For Bone Formation and Bone Resorption

D. Baylink, M. Kraenzlin, A. K. Taylor, 1989 .

Purification and N-terminal sequence of two tartrate-resistant acid phosphatases type-5 from the hairy cell leukemia spleen.

S. Mohan, K. Lau, D. Baylink, 1989, Biochemical and biophysical research communications.

Parathyroidectomy in primary hyperparathyroidism: preoperative localization and routine biopsy of unaltered glands are not necessary.

M. Oberholzer, D. Oertli, H. Haas, 1995, Surgery.

Protein metabolism assessed by 1-13C leucine infusions in patients undergoing bone marrow transplantation.

A. Gratwohl, U. Keller, A. Thélin, 1990, JPEN. Journal of parenteral and enteral nutrition.

Effects of IGF-I combined with GH on glucocorticoid-induced changes of bone and connective tissue turnover in man.

U. Keller, K. Berneis, M. Kraenzlin, 1999, The Journal of endocrinology.

Metabolomics and Their Ability to Distinguish Thyroid Disorders: A Retrospective Pilot Study

P. Schuetz, A. Kutz, B. Mueller, 2019, Hormone and Metabolic Research.

Metabolomics for Prediction of Relapse in Graves' Disease: Observational Pilot Study

P. Schuetz, A. Kutz, B. Mueller, 2018, Front. Endocrinol..

A cohort of 17 patients with kyphoscoliotic Ehlers–Danlos syndrome caused by biallelic mutations in FKBP14: expansion of the clinical and mutational spectrum and description of the natural history

C. Fauth, C. Bönnemann, J. Pilch, 2017, Genetics in Medicine.

Kyphoscoliotic type of Ehlers-Danlos Syndrome (EDS VIA) in six Egyptian patients presenting with a homogeneous clinical phenotype

C. Giunta, M. Rohrbach, E. Abdalla, 2014, European Journal of Pediatrics.

Nevo syndrome is allelic to the kyphoscoliotic type of the Ehlers–Danlos syndrome (EDS VIA)

H. Brunner, L. Al-Gazali, C. Giunta, 2005, American journal of medical genetics. Part A.

An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease.

A. Huber, M. Kraenzlin, A. Bock, 2004, Clinica chimica acta; international journal of clinical chemistry.

Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production.

A. Keshavarzian, S. Bloom, J. Burrin, 1985, The American journal of medicine.

CAN INHIBITION OF HORMONE SECRETION BE ASSOCIATED WITH ENDOCRINE TUMOUR SHRINKAGE?

S. Bloom, M. Kraenzlin, S. Wood, 1983, The Lancet.

Comparison of Five TSH-Receptor Antibody Assays in Graves’ disease: results from an observational pilot study

P. Schuetz, A. Kutz, B. Mueller, 2019, BMC Endocrine Disorders.

Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial

M. Christ-Crain, M. Beat, M. Kraenzlin, 2004, Osteoporosis International.

Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial

L. Grize, T. Wischer, M. Kraenzlin, 2013, Osteoporosis International.

Discriminatory Ability of Quantitative Ultrasound Parameters and Bone Mineral Density in a Population‐Based Sample of Postmenopausal Women With Vertebral Fractures: Results of the Basel Osteoporosis Study

D. Hans, A. Tyndall, C. Bachmeier, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

HMG-CoA reductase inhibitors and the risk of fractures.

H Jick, R. Schlienger, H. Jick, 2000, JAMA.

Possible beneficial effect of bisphosphonates in osteonecrosis of the knee

M. Kraenzlin, C. Meier, C. Kraenzlin, 2010, Knee Surgery, Sports Traumatology, Arthroscopy.

Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance.

S. Bloom, M. Kraenzlin, G. Williams, 1986, Scandinavian journal of gastroenterology. Supplement.

Correction: The Zinc Transporter SLC39A13/ZIP13 Is Required for Connective Tissue Development; Its Involvement in BMP/TGF-β Signaling Pathways

J. Beckmann, O. Ohara, T. Hirano, 2008, PLoS ONE.

[Epidemiology of osteoporosis].

P Burckhardt, J. Bonjour, P. Burckhardt, 1997, Schweizerische medizinische Wochenschrift.

Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus

C. Cooper, R. Eastell, W. Leslie, 2016 .

Use of β-Blockers and Risk of Fractures

R. Schlienger, S. Jick, C. Meier, 2004 .

Mutations in PLOD3, encoding lysyl hydroxylase 3, cause a complex connective tissue disorder including recessive dystrophic epidermolysis bullosa-like blistering phenotype with abnormal anchoring fibrils and type VII collagen deficiency.

J. Uitto, J. McGrath, A. Kariminejad, 2019, Matrix biology : journal of the International Society for Matrix Biology.

Indications to teriparatide treatment in patients with osteoporosis.

R. Rizzoli, M. Krieg, K. Lippuner, 2011, Swiss medical weekly.

Use of depot medroxyprogesterone acetate and fracture risk.

S. Jick, M. Kraenzlin, Y. Brauchli, 2010, The Journal of clinical endocrinology and metabolism.

Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women

W. Herrmann, M. Herrmann, Marga Sand-Hill, 2005, Clinical chemistry and laboratory medicine.

External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients.

M. Christ-Crain, P. Schuetz, A. Kutz, 2017, European journal of endocrinology.

Bone mineral density and its determinants in men with opioid dependence

L. Grize, M. Kraenzlin, C. Meier, 2015, Journal of Bone and Mineral Metabolism.

Statins and fracture risk.

R. Schlienger, H. Jick, C. Meier, 2001, JAMA.

Rebound Effect and Escape of Diarrhea Inhibition Using Sandostatin® in VIPoma Patients

C. Beglinger, S. Bloom, K. Gyr, 1989 .

Effect of long acting somatostatin-analogue, SMS 201995, on gut hormone secretion in normal subjects

T. Adrian, S. Bloom, M. Kraenzlin, 1985, Experientia.

Prospective evaluation of risk of vertebral fractures using quantitative ultrasound measurements and bone mineral density in a population-based sample of postmenopausal women: results of the Basel Osteoporosis Study

D. Hans, A. Tyndall, C. Buitrago-Téllez, 2008, Annals of the rheumatic diseases.

Comparison of Three Bone Ultrasounds for the Discrimination of Subjects With and Without Osteoporotic Fractures Among 7562 Elderly Women

R. Rizzoli, J. Cornuz, A. Tyndall, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Prevention of Bone Loss in Paraplegics Over 2 Years With Alendronate

K. Lippuner, M. Kraenzlin, G. Zäch, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Gonadal hormones and their influence on skeletal health in men

M. Kraenzlin, C. Meier, 2007 .

Use of thiazolidinediones and fracture risk.

H. Jick, S. Jick, C. Meier, 2008, Archives of internal medicine.

Decreased bone turnover in children and adolescents with well controlled type 1 diabetes

R. Rizzoli, L. Marchand, A. Maggio, 2010, Journal of pediatric endocrinology & metabolism : JPEM.

The influence of gonadal hormones on skeletal health in men

M. Kraenzlin, C. Meier, 2013, Osteologie.

Risk of Fractures with Glitazones

M. Kraenzlin, M. Bodmer, C. Meier, 2009, Drug safety.

Prediction of Hip Fracture Risk by Quantitative Ultrasound in More Than 7000 Swiss Women ≥70 Years of Age: Comparison of Three Technologically Different Bone Ultrasound Devices in the SEMOF Study

Florian Hartl, Jacques Cornuz, Didier Hans, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of a general school-based physical activity intervention on bone mineral content and density: a cluster-randomized controlled trial.

R. Rizzoli, L. Zahner, C. Schindler, 2011, Bone.

Parathyroid hormone analogues in the treatment of osteoporosis

M. Kraenzlin, C. Meier, 2011, Nature Reviews Endocrinology.

Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice

B. Müller, M. Kraenzlin, C. Meier, 2009, Journal of Bone and Mineral Metabolism.

Intravenous Bisphosphonates for Postmenopausal Osteoporosis: Safety Profiles of Zoledronic Acid and Ibandronate in Clinical Practice

M. Kraenzlin, C. Meier, C. Kraenzlin, 2013, Clinical Drug Investigation.

Changes in bone mineral content after surgical treatment of morbid obesity.

U. Keller, S. Bilz, M. Kraenzlin, 2004, Metabolism: clinical and experimental.

3-Year follow-up results of bone mineral content and density after a school-based physical activity randomized intervention trial.

R. Rizzoli, L. Zahner, C. Schindler, 2013, Bone.

Hyperthyroidism due to non-tumoural inappropriate TSH secretion. Effect of a long-acting somatostatin analogue (SMS 201-995).

J. Burrin, S. Bloom, M. Kraenzlin, 1986, Acta endocrinologica.

Free Thyroxine Levels are Associated with Cold Induced Thermogenesis in Healthy Euthyroid Individuals

I. Burger, A. Becker, M. Betz, 2021, Frontiers in Endocrinology.

Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women?

M. Kraenzlin, C. Meier, 2007, Nature Clinical Practice Endocrinology &Metabolism.

Fluoride therapy for osteoporosis: A review of dose response, duration of treatment, and skeletal sites of action

C. Libanati, E. Schulz, D. Baylink, 2007, Calcified Tissue International.

3-Year follow-up results of bone mineral content and density after a school-based physical activity randomized intervention trial.

R. Rizzoli, L. Zahner, C. Schindler, 2013, Bone.

Use of Bone Turnover Markers in the Real World: Are We There Yet?

M. Seibel, M. Kraenzlin, C. Meier, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.